C.Q. Pharmaceutical Holding Co Ltd
C.Q. Pharmaceutical Holding Co., Ltd. engages in the wholesale and retail of medicines and medical devices. The company is involved in the pharmaceutical commerce, warehousing logistics, pharmaceutical industry, and research and development businesses. It also engages in the hospital pure sales, commercial wholesale, retail chain, warehousing logistics, and supply chain value-added services for d… Read more
C.Q. Pharmaceutical Holding Co Ltd (000950) - Net Assets
Latest net assets as of September 2025: CN¥16.47 Billion CNY
Based on the latest financial reports, C.Q. Pharmaceutical Holding Co Ltd (000950) has net assets worth CN¥16.47 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥67.71 Billion) and total liabilities (CN¥51.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥16.47 Billion |
| % of Total Assets | 24.33% |
| Annual Growth Rate | 23.08% |
| 5-Year Change | 57.09% |
| 10-Year Change | 861.03% |
| Growth Volatility | 124.57 |
C.Q. Pharmaceutical Holding Co Ltd - Net Assets Trend (1996–2024)
This chart illustrates how C.Q. Pharmaceutical Holding Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for C.Q. Pharmaceutical Holding Co Ltd (1996–2024)
The table below shows the annual net assets of C.Q. Pharmaceutical Holding Co Ltd from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥16.46 Billion | +6.17% |
| 2023-12-31 | CN¥15.51 Billion | +22.01% |
| 2022-12-31 | CN¥12.71 Billion | +8.02% |
| 2021-12-31 | CN¥11.77 Billion | +12.27% |
| 2020-12-31 | CN¥10.48 Billion | +18.27% |
| 2019-12-31 | CN¥8.86 Billion | +9.30% |
| 2018-12-31 | CN¥8.11 Billion | +11.80% |
| 2017-12-31 | CN¥7.25 Billion | +595.05% |
| 2016-12-31 | CN¥1.04 Billion | -39.10% |
| 2015-12-31 | CN¥1.71 Billion | -17.43% |
| 2014-12-31 | CN¥2.07 Billion | -14.89% |
| 2013-12-31 | CN¥2.44 Billion | +0.24% |
| 2012-12-31 | CN¥2.43 Billion | -3.21% |
| 2011-12-31 | CN¥2.51 Billion | +5.35% |
| 2010-12-31 | CN¥2.38 Billion | +4.22% |
| 2009-12-31 | CN¥2.29 Billion | +132.51% |
| 2008-12-31 | CN¥984.19 Million | +32.25% |
| 2007-12-31 | CN¥744.17 Million | +40.52% |
| 2006-12-31 | CN¥529.58 Million | +18.97% |
| 2005-12-31 | CN¥445.16 Million | +125.45% |
| 2004-12-31 | CN¥197.45 Million | +6.39% |
| 2003-12-31 | CN¥185.59 Million | -43.60% |
| 2002-12-31 | CN¥329.08 Million | -22.71% |
| 2001-12-31 | CN¥425.75 Million | -0.55% |
| 2000-12-31 | CN¥428.11 Million | +4.42% |
| 1999-12-31 | CN¥409.98 Million | +298.63% |
| 1998-12-31 | CN¥102.85 Million | +2.14% |
| 1997-12-31 | CN¥100.69 Million | +104.88% |
| 1996-12-31 | CN¥49.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to C.Q. Pharmaceutical Holding Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 704268300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥7.04 Billion | 62.18% |
| Common Stock | CN¥1.73 Billion | 15.26% |
| Other Components | CN¥2.56 Billion | 22.57% |
| Total Equity | CN¥11.33 Billion | 100.00% |
C.Q. Pharmaceutical Holding Co Ltd Competitors by Market Cap
The table below lists competitors of C.Q. Pharmaceutical Holding Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HANOF
PINK:HANOF
|
$540.45 Million |
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
$540.76 Million |
|
Ã
landsbanken Abp
LSE:0O2M
|
$540.77 Million |
|
CanSino Biologics Inc
PINK:CASBF
|
$540.94 Million |
|
Molson Coors Canada Inc
TO:TPX-B
|
$540.28 Million |
|
Zhejiang Entive Smart Kitchen Appliance Co. Ltd.
SHE:300911
|
$540.15 Million |
|
Nantong Jinghua Pharmaceutical Co Ltd
SHE:002349
|
$539.99 Million |
|
Sterlite Technologies Limited
NSE:STLTECH
|
$539.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in C.Q. Pharmaceutical Holding Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,245,861,308 to 11,327,167,000, a change of 81,305,692 (0.7%).
- Net income of 282,993,623 contributed positively to equity growth.
- Dividend payments of 1,120,087,818 reduced retained earnings.
- Other factors increased equity by 918,399,887.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥282.99 Million | +2.5% |
| Dividends Paid | CN¥1.12 Billion | -9.89% |
| Other Changes | CN¥918.40 Million | +8.11% |
| Total Change | CN¥- | 0.72% |
Book Value vs Market Value Analysis
This analysis compares C.Q. Pharmaceutical Holding Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 37.41x to 0.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | CN¥0.15 | CN¥5.73 | x |
| 1997-12-31 | CN¥0.31 | CN¥5.73 | x |
| 1998-12-31 | CN¥0.32 | CN¥5.73 | x |
| 1999-12-31 | CN¥1.28 | CN¥5.73 | x |
| 2000-12-31 | CN¥1.33 | CN¥5.73 | x |
| 2001-12-31 | CN¥1.33 | CN¥5.73 | x |
| 2002-12-31 | CN¥1.03 | CN¥5.73 | x |
| 2003-12-31 | CN¥0.58 | CN¥5.73 | x |
| 2004-12-31 | CN¥0.62 | CN¥5.73 | x |
| 2005-12-31 | CN¥0.53 | CN¥5.73 | x |
| 2006-12-31 | CN¥0.87 | CN¥5.73 | x |
| 2007-12-31 | CN¥2.49 | CN¥5.73 | x |
| 2008-12-31 | CN¥2.08 | CN¥5.73 | x |
| 2009-12-31 | CN¥4.72 | CN¥5.73 | x |
| 2010-12-31 | CN¥3.93 | CN¥5.73 | x |
| 2011-12-31 | CN¥3.95 | CN¥5.73 | x |
| 2012-12-31 | CN¥3.99 | CN¥5.73 | x |
| 2013-12-31 | CN¥4.80 | CN¥5.73 | x |
| 2014-12-31 | CN¥3.43 | CN¥5.73 | x |
| 2015-12-31 | CN¥2.83 | CN¥5.73 | x |
| 2016-12-31 | CN¥0.59 | CN¥5.73 | x |
| 2017-12-31 | CN¥3.89 | CN¥5.73 | x |
| 2018-12-31 | CN¥4.24 | CN¥5.73 | x |
| 2019-12-31 | CN¥4.67 | CN¥5.73 | x |
| 2020-12-31 | CN¥5.11 | CN¥5.73 | x |
| 2021-12-31 | CN¥5.68 | CN¥5.73 | x |
| 2022-12-31 | CN¥6.16 | CN¥5.73 | x |
| 2023-12-31 | CN¥6.52 | CN¥5.73 | x |
| 2024-12-31 | CN¥6.40 | CN¥5.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently C.Q. Pharmaceutical Holding Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.35%
- • Asset Turnover: 1.21x
- • Equity Multiplier: 5.88x
- Recent ROE (2.50%) is below the historical average (5.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 21.86% | 3.22% | 2.36x | 2.89x | CN¥5.83 Million |
| 1997 | 25.63% | 6.45% | 1.49x | 2.67x | CN¥15.74 Million |
| 1998 | 19.51% | 5.17% | 1.19x | 3.18x | CN¥9.78 Million |
| 1999 | 7.23% | 7.74% | 0.59x | 1.59x | CN¥-11.37 Million |
| 2000 | 8.26% | 9.14% | 0.46x | 1.94x | CN¥-7.45 Million |
| 2001 | 1.02% | 0.92% | 0.47x | 2.34x | CN¥-38.22 Million |
| 2002 | -29.91% | -29.45% | 0.37x | 2.75x | CN¥-131.34 Million |
| 2003 | -77.32% | -40.28% | 0.50x | 3.83x | CN¥-162.05 Million |
| 2004 | 4.03% | 2.76% | 0.41x | 3.55x | CN¥-11.78 Million |
| 2005 | -25.59% | -13.16% | 0.34x | 5.72x | CN¥-60.95 Million |
| 2006 | 32.47% | 8.45% | 0.93x | 4.15x | CN¥56.97 Million |
| 2007 | 19.54% | 14.22% | 0.85x | 1.62x | CN¥71.03 Million |
| 2008 | 28.20% | 18.82% | 0.58x | 2.58x | CN¥176.04 Million |
| 2009 | 7.44% | 7.79% | 0.58x | 1.64x | CN¥-58.23 Million |
| 2010 | 5.60% | 6.37% | 0.51x | 1.74x | CN¥-104.01 Million |
| 2011 | 3.79% | 3.51% | 0.60x | 1.81x | CN¥-148.65 Million |
| 2012 | 5.01% | 3.65% | 0.64x | 2.14x | CN¥-121.04 Million |
| 2013 | 0.30% | 0.21% | 0.52x | 2.69x | CN¥-235.85 Million |
| 2014 | -17.48% | -12.18% | 0.43x | 3.30x | CN¥-568.23 Million |
| 2015 | 23.09% | 2.03% | 3.19x | 3.57x | CN¥223.23 Million |
| 2016 | 25.48% | 1.29% | 3.75x | 5.26x | CN¥160.63 Million |
| 2017 | 16.47% | 5.22% | 1.39x | 2.26x | CN¥434.51 Million |
| 2018 | 9.44% | 2.68% | 1.28x | 2.75x | CN¥-41.30 Million |
| 2019 | 9.77% | 2.33% | 1.33x | 3.16x | CN¥-18.52 Million |
| 2020 | 10.01% | 1.96% | 1.07x | 4.80x | CN¥773.69K |
| 2021 | 10.24% | 1.61% | 1.26x | 5.06x | CN¥23.35 Million |
| 2022 | 8.94% | 1.40% | 1.19x | 5.37x | CN¥-112.89 Million |
| 2023 | 5.55% | 0.80% | 1.23x | 5.65x | CN¥-499.95 Million |
| 2024 | 2.50% | 0.35% | 1.21x | 5.88x | CN¥-849.72 Million |
Industry Comparison
This section compares C.Q. Pharmaceutical Holding Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $5,507,461,339
- Average return on equity (ROE) among peers: 8.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| C.Q. Pharmaceutical Holding Co Ltd (000950) | CN¥16.47 Billion | 21.86% | 3.11x | $540.32 Million |
| Shenzhen Glory Medical Co Ltd (002551) | $2.82 Billion | 2.12% | 0.68x | $269.33 Million |
| Shandong Realcan Pharmaceutical Co Ltd (002589) | $5.69 Billion | 0.36% | 1.81x | $435.98 Million |
| Qingdao Baheal Medical INC. (301015) | $1.50 Billion | 18.20% | 1.70x | $460.79 Million |
| China Meheco Co Ltd (600056) | $382.07 Million | 11.69% | 1.02x | $1.02 Billion |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) | $3.90 Billion | 7.38% | 0.25x | $3.04 Billion |
| Liaoning Cheng Da Co Ltd (600739) | $21.37 Billion | 6.77% | 0.66x | $1.40 Billion |
| Jointown Pharmaceutical Group Co Ltd (600998) | $4.84 Billion | 8.53% | 2.06x | $1.61 Billion |
| Guangxi Liuzhou Pharm Co Ltd (603368) | $3.57 Billion | 11.25% | 1.12x | $667.23 Million |